Royal Philips and Paige, a New York-based healthcare startup, are working together to put AI in the hands of pathologists.
The first step of the new collaboration involves giving pathologists access to Paige’s prostate cancer software, Paige Prostate. Once a lab has been converted to a digital workflow, it can use the software to automatically detect and localize signs of prostate cancer.
Philips has said it will be offering Paige Prostate, which has already received CE approval, to pathology labs throughout Europe beginning in 2020.
“We want to empower pathologists with the latest computational pathology solutions to enhance the diagnosis and treatment of cancer,” Marlon Thompson, business leader of digital & computational pathology at Philips, said in a prepared statement. “Through our open digital pathology platform approach, we team up with leading computational pathology solution providers, such as Paige, to create the ultimate end-to-end oncology workflow for our customers.”
“Pathology is transforming into a digital discipline and holds a strong promise for using AI solutions to aid, streamline, and enhance decision-making,” Leo Grady, CEO of Paige, said in the same statement. “Together with digital pathology providers, starting with Philips, one of the leaders in the clinical digital pathology space, we want to convert this promise into a clinical reality that supports pathologists and their patients."
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.